Skip to content
Xerava(eravacycline)
Xerava (eravacycline) is a small molecule pharmaceutical. Eravacycline was first approved as Xerava on 2018-08-27. It is used to treat intraabdominal infections in the USA. It has been approved in Europe to treat bacterial infections and infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
Trade Name
FDA
EMA
Xerava
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Eravacycline dihydrochloride
Tradename
Company
Number
Date
Products
XERAVATetraphase PharmaceuticalsN-211109 RX2018-08-27
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
xeravaNew Drug Application2020-06-03
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
intraabdominal infections—D059413—
Agency Specific
FDA
EMA
Expiration
Code
ERAVACYCLINE DIHYDROCHLORIDE, XERAVA, TETRAPHASE PHARMS
2028-08-27GAIN
2023-08-27NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Eravacycline Dihydrochloride, Xerava, Tetraphase Pharms
109611902037-10-19DP
115780442037-10-19DP
89068872030-12-28DP
87962452029-08-07U-2380
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01A: Tetracycline antibiotics
— J01AA: Tetracyclines
— J01AA13: Eravacycline
HCPCS
Code
Description
J0122
Injection, eravacycline, 1 mg
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Intraabdominal infectionsD059413—12——3
Urinary tract infectionsD014552EFO_0003103N39.0——1——1
AppendicitisD001064EFO_0007149K37——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hematologic neoplasmsD019337—1———1
NeutropeniaD009503D70—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bacterial infectionsD001424A491————1
Chronic kidney failureD007676EFO_0003884N18.61————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameERAVACYCLINE
INNeravacycline
Description
Eravacycline is a member of tetracyclines.
Classification
Small molecule
Drug classantibiotics (tetracycline derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4C[C@H]3C[C@@H]12
Identifiers
PDB—
CAS-ID1207283-85-9
RxCUI—
ChEMBL IDCHEMBL1951095
ChEBI ID—
PubChem CID54726192
DrugBankDB12329
UNII ID07896928ZC (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Xerava - Innoviva, Inc.
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Xerava - La Jolla Pharmaceutical Company
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 947 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
729 adverse events reported
View more details